1. Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma.
- Author
-
Ma R, Zhang Q, Liu Y, Li H, Chen H, Zhang Q, Qiao J, Qi K, Shen G, Sun C, Song X, Cao J, Cheng H, Zhu F, Yan Z, Sang W, Li D, Sun H, Zheng J, Li Z, Xu K, and Chen W
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Treatment Outcome, Receptors, Chimeric Antigen, Cytokine Release Syndrome therapy, Platelet Function Tests, Multiple Myeloma therapy, Multiple Myeloma mortality, Multiple Myeloma pathology, Immunotherapy, Adoptive, Blood Platelets
- Abstract
The influence of chimeric antigen receptor T (CAR-T) cell therapy on platelet function in relapsed/refractory (R/R) multiple myeloma (MM) has not been thoroughly investigated. Our cohort comprised fifty MM patients treated with CAR-T cells. The mean platelet closure time (PCT) induced by collagen/adenosine diphosphate (CADP) in peripheral blood was significantly prolonged before lymphodepletion (195.24 ± 11.740 s) and notably reduced post-CAR-T cell therapy (128.02 ± 5.60 s), with a statistically significant improvement (67.22, 95% CI 46.91-87.53, P < 0.001). This post-treatment PCT was not significantly different from that of healthy controls (10.64, 95% CI 1.11-22.40, P > 0.05). Furthermore, a pronounced enhancement in PCT was observed in patients with a response greater than partial remission (PR) following CAR-T cell infusion compared to pre-treatment values (P < 0.001). An extended PCT was also associated with a less favorable remission status. In patients with cytokine release syndrome (CRS) grades 0-2, those with a PCT over 240.5 s exhibited a shorter progression-free survival (PFS), with median PFS times of 10.2 months for the PCT > 240.5 s group versus 22.0 months for the PCT ≤ 240.5 s group. Multivariate analysis revealed that a PCT value exceeding 240.5 s is an independent prognostic factor for overall survival (OS) in R/R MM patients after CAR-T cell therapy. The study demonstrates that CAR-T cell therapy enhances platelet function in R/R MM patients, and PCT emerges as a potential prognostic biomarker for the efficacy of CAR-T cell therapy., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF